Liquidia Technologies (NASDAQ:LQDA) Insider Jason Adair Sells 3,670 Shares

Key Points

• Liquidia Technologies insider Jason Adair sold 3,670 shares at an average price of $23.41, reducing his ownership by 2.05% to a total of 175,690 shares valued at approximately $4.1 million.
• The company's stock recently traded around $23.16, with a market capitalization of $1.99 billion and a 12-month price range between $9.71 and $29.94.
• Liquidia Technologies experienced a significant year-over-year revenue increase of 141.5%, reporting $8.84 million in revenue for the last quarter, despite a loss of ($0.49) earnings per share.

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 3,670 shares of the firm's stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $85,914.70. Following the sale, the insider directly owned 175,690 shares in the company, valued at approximately $4,112,902.90. This represents a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jason Adair also recently made the following trade(s):

• On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia Technologies stock. The stock was sold at an average price of $29.05, for a total value of $13,101.55.
• On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia Technologies stock. The stock was sold at an average price of $29.05, for a total value of $13,101.55.
• On Thursday, August 28th, Jason Adair sold 26,057 shares of Liquidia Technologies stock. The stock was sold at an average price of $27.86, for a total value of $725,948.02.
• On Monday, July 28th, Jason Adair sold 454 shares of Liquidia Technologies stock. The stock was sold at an average price of $19.54, for a total value of $8,871.16.

Liquidia Technologies Price Performance

LQDA stock traded up $0.39 during midday trading on Wednesday, hitting $23.16. The company's stock had a trading volume of 1,994,182 shares, compared to its average volume of 1,944,347. Liquidia Technologies, Inc. has a 12 month low of $9.71 and a 12 month high of $29.94. The company has a quick ratio of 2.41, a current ratio of 2.49 and a debt-to-equity ratio of 9.84. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -13.62 and a beta of 0.15. The company has a 50 day moving average of $25.00 and a two-hundred day moving average of $18.47.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The business had revenue of $8.84 million during the quarter, compared to the consensus estimate of $3.90 million. The business's revenue for the quarter was up 141.5% on a year-over-year basis. On average, analysts expect that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LQDA. Jefferies Financial Group started coverage on shares of Liquidia Technologies in a report on Friday, August 15th. They issued a "buy" rating and a $43.00 price target for the company. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Liquidia Technologies in a report on Monday, October 6th. Needham & Company LLC increased their price target on Liquidia Technologies from $32.00 to $36.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Liquidia Technologies in a report on Wednesday, October 8th. Finally, Wells Fargo & Company lifted their price objective on shares of Liquidia Technologies from $25.00 to $31.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $32.38.

Institutional Investors Weigh In On Liquidia Technologies

A number of hedge funds have recently made changes to their positions in LQDA. Tyro Capital Management LLC purchased a new stake in shares of Liquidia Technologies during the 2nd quarter worth $15,473,000. CenterBook Partners LP lifted its stake in shares of Liquidia Technologies by 811.7% during the 2nd quarter. CenterBook Partners LP now owns 1,103,850 shares of the company's stock worth $13,754,000 after purchasing an additional 982,778 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Liquidia Technologies by 446.7% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 461,248 shares of the company's stock worth $6,803,000 after purchasing an additional 376,872 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Liquidia Technologies by 157.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 482,822 shares of the company's stock worth $6,016,000 after purchasing an additional 295,104 shares during the last quarter. Finally, Marshall Wace LLP increased its position in shares of Liquidia Technologies by 58.6% during the second quarter. Marshall Wace LLP now owns 660,762 shares of the company's stock worth $8,233,000 after purchasing an additional 244,235 shares in the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.